Medicilon (Chuansha) Inc. won the "Development Potential Award" of Chuansha New Town

On March 20, Chuansha New Town grandly held the 2024 Enterprise Commendation Event and Investment Promotion Launching Ceremony. At the meeting, Medicilon (Chuansha) Inc., a subsidiary of Shanghai Medicilon Inc. (Medicilon), relied on its outstanding performance and strong development momentum in the field of biopharmaceutical, won the "Development Potential Award" for the 2023 Chuansha New Town Economic Work Advanced Unit.

Development Potential Award.webp

As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon is well-deserved for the award. Over the past two decades, Medicilon has been deeply involved in the field of biopharmaceutical preclinical research and development. Medicilon has not only continue to shine in the field of traditional chemical drugs, but also proactively planning ahead in emerging tracks such as bi/multi-specific antibodies, ADCs, PROTACs, mRNA vaccines, small nucleic acid drugs, cells and immunity, and have built a series of efficient and cutting-edge technology service platforms. By the end of 2023, Medicilon has participated in the research and development of 421 new drugs and generic drug projects that have been approved for clinical use.

Winning the "Development Potential Award" this time is not only an affirmation of Medicilon's own empowerment achievements in the past year, but also recognition of its future development potential. In the future, Medicilon will continue to take technological innovation as the driving force, keep up with industry development trends, explore more cutting-edge technologies, continue to innovate and improve the R&D service platform, and inject continuous innovative vitality into the vigorous development of the biopharmaceutical industry!

此博客中的热门博文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Pharmacokinetics Services

Pharmacokinetics Services Our pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai government. Preclinical Pharmacokinetics Method development and validation (GLP,Non-GLP) Bioanalysis Pharmacokinetics (Tumor bearing rodents, Bioavailability, Crossover studies, Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB penetration ) Stability in vehicles and plasma Drug interaction studies In vitro metabolic stability CYP 450 inhibition Plasma protein binding studies Distribution studies Excretion studies Prediction an...

阅读全文

Shanghai Medicilon Inc.

搜索此博客